Page results
-
Our team deliver care to people with MS and aim to provide specialist services, share information on how to manage symptoms, offer education sessions, medication options and rehabilitation services.
-
The Neurometabolic unit provides a unique range of investigations and clinical laboratory advice encompassing mitochondrial, neurotransmitter, pterin and amino acid disorders.
-
The clinical management of neuromuscular muscle wasting diseases such as motor neuron disease, myasthenia gravis, muscular dystrophy and peripheral neuropathy.
-
Typically, patient care is multidisciplinary led by consultant neuro-ophthalmologists and neurologists.
-
The department is responsible for a wide range of neurophysiological procedures, principally electromyography (EMG) and nerve conduction studies, EMG-guided botulinum toxin (BoTox) injections, electroencephalography (EEG), evoked potentials (EPs) and intra-operative monitoring (IOM)
-
The head and neck speech and language therapy team provide a highly specialist service to both inpatients and outpatients who may experience difficulty swallowing or speaking following treatment for head and neck cancer.
-
The plasma exchange service at the National Hospital treats patients with neuroimmunological diseases such as Guillain-Barré syndrome and myasthenia gravis.
-
We provide a specialist spinal surgery service including treatment of degenerative spinal conditions, artificial discs, spinal injury, spinal tumours (intra and extra dural, including metastatic disease), scoliosis and syringomyelia.
-
AutoLab is a dual haematology and biochemistry laboratory which operates as a public private partnership between Sonic Healthcare pty (The Doctors Laboratory) and UCLH NHS Foundation Trust Hospitals Laboratories.
-
Autoimmune serology is provided for: Connective tissue diseases, Endocrine diseases, Liver diseases, Rheumatic diseases, Skin diseases, Thyroid diseases.
File results
-
FOI/2024/0431 - Hospital patient monitoring system on wards
-
FOI/2024/0421 - Capital staffing nurses/ approved framework agencies/ escalated rates
-
FOI/2024/0423 - Giant cell arteritis (GCA) patient treatment
-
FOI/2024/0425 - Freedom of Information (FOI) structure, banding and job titles
-
FOI/2024/0426 - Agency staff spend for nursing, HCAs, pharmacists, occupational therapists and physiotherapists
-
FOI/2024/0428 - Physiotherapy/ occupational recruitment for 2023
-
FOI/2024/0440 - Patient reported outcome measures (PROMs) in oncology
-
FOI/2024/0455 - Information Governance structure
-
FOI/2024/0450 - Trust-wide obesity and weight management strategy
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer